Abstract

One of the most used hormonal contraceptive treatments in the world, oral contraceptives (OCs) provide substantial advantages for hormone management and family planning. However, a lot of study has been done on their possible effects on breast tissue and long-term health hazards, including breast cancer. This study synthesizes data from epidemiological and clinical research to examine the intricate relationship between OC usage, mammographic breast density, and breast cancer risk. The hormonal makeup of OCs, especially estrogen and progestin, may have an impact on mammographic breast density, a known independent risk factor for breast cancer. The slightly increased risk of breast cancer seen in current or recent OC users is therefore believed to be partially mediated by higher breast density. Key findings highlight that the degree of risk varies depending on factors such as age, duration of OC use, hormonal formulation, and genetic predispositions. While the absolute increase in breast cancer risk associated with OCs remains small for most women, it holds greater significance for those with high-risk profiles. The review also identifies gaps in knowledge regarding the effects of modern low-dose OC formulations and variations across diverse populations.   This synthesis emphasizes the importance of informed contraceptive choices, individualized risk assessments, and enhanced screening protocols for women at higher risk of breast cancer. Furthermore, it underscores the need for interdisciplinary research to explore molecular mechanisms, develop safer contraceptive options, and address unresolved questions. By advancing our understanding of these relationships, healthcare providers can better guide women in making decisions that prioritize both reproductive health and long-term well-being.